Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: Analysis of the 3-Year Phase 3 Rising Up Study

• Главные авторы: Norito Katoh (Автор), Masanori Ikeda (Автор), Yukihiro Ohya (Автор), Hiroyuki Murota (Автор), Xiaofei Hu (Автор), John Liu (Автор), Hayato Niiyama (Автор), Takuya Sasaki (Автор), Eliza M. Raymundo (Автор), Hidehisa Saeki (Автор)
• Формат: ‌
• Опубликовано: Adis, Springer Healthcare, 2023-12-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Abstract Introduction Upadacitinib is an oral Janus kinase inhibitor approved in multiple countries for moderate-to-severe atopic dermatitis (AD). Here we present long-term data for up to 3 years of continuous upadacitinib treatment in Japanese patients with AD. Methods Rising Up was a phase 3, rand...